Therapeutic options to target angiogenesis in human malignancies
- 25 October 2006
- journal article
- review article
- Published by Taylor & Francis in Emerging Drugs
- Vol. 11 (4), 635-650
- https://doi.org/10.1517/14728214.11.4.635
Abstract
(2006). Therapeutic options to target angiogenesis in human malignancies. Expert Opinion on Emerging Drugs: Vol. 11, No. 4, pp. 635-650. doi: 10.1517/14728214.11.4.635Keywords
This publication has 110 references indexed in Scilit:
- Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Autocrine PDGFR signaling promotes mammary cancer metastasisJournal of Clinical Investigation, 2006
- Flare in Neuropathy Following Rituximab Therapy for Waldenstrom’s MacroglobulinemiaJournal of Clinical Oncology, 2006
- Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2006
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursEuropean Journal Of Cancer, 2005
- Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancerEuropean Journal Of Cancer, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEuropean Journal Of Cancer, 1996
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993